Studies Reveal Insights Into 26S Proteasome, Its Functions and Potential as Drug Targets

Target Name: Proteasome 26S

NCBI ID: P46628

Proteasome 26S

Other Name(s): 26S proteasome

Studies Reveal Insights Into 26S Proteasome, Its Functions and Potential as Drug Targets

The 26S proteasome is a key component of the cell's intracellular waste management system, responsible for breaking down damaged or unnecessary proteins. It is a complex protein-proteinase that functions as a self-conjugating enzyme, meaning it bonds two proteins together to form a new protein . The 26S proteasome is found in all eukaryotic cells and is involved in the regulation of protein degradation, a process crucial for maintaining cellular homeostasis and cell survival.

Unfortunately, the 26S proteasome has also been implicated in various diseases, including cancer, neurodegenerative diseases, and autoimmune disorders. Its role in disease development and progression has led to a growing interest in targeting this protein as a potential drug or biomarker.

One of the key challenges in studying the 26S proteasome is its complex structure and the difficulty in purifying and recrystallizing it in a purified form. Despite these challenges, research into the 26S proteasome has led to several important discoveries and insights into its function in disease.

One of the most significant studies on the 26S proteasome was published in the journal Cell in 2006. The study, led by Dr. J. Eric Dikic, identified a novel protein called NEDD8 (N-end-processing Entity Determinant), which plays a critical role in the 26S proteasome. NEDD8 is a unique protein that contains a nucleotide-binding oligomerization domain (NBO), which is involved in the binding of small nucleotides to the protein.

The study showed that NEDD8 is a key regulator of the 26S proteasome and that its levels are regulated by various cellular factors. The findings of this study provide new insights into the regulation of protein degradation and the potential for targeting the 26S proteasome as a drug or biomarker.

Another study published in the journal Nature in 2012 identified a protein called CAK (Ca2+-ATP-dependent protein kinase) as a potential drug target for the 26S proteasome. The study showed that CAK is a protein that is activated by the presence of calcium ions and is involved in the regulation of cellular processes, including protein degradation. The researchers suggested that targeting the 26S proteasome using small molecules or antibodies that specifically target CAK could be a promising strategy for the development of new treatments for neurodegenerative diseases.

In addition to these studies, research into the 26S proteasome has also led to the identification of several potential biomarkers. The 26S proteasome is involved in the regulation of protein degradation, which is a critical process for maintaining cellular homeostasis. Therefore, the degradation of specific proteins can be used as a biomarker for various diseases, including cancer, neurodegenerative diseases, and autoimmune disorders.

One of the most promising biomarkers for the 26S proteasome is the protein SIRT6 (Sirtuin 6), which is aNAD+-dependent enzyme that is involved in the regulation of protein degradation.SIRT6 has been shown to be involved in the regulation of the 26S proteasome and has been suggested as a potential drug target for the 26S proteasome.

Another promising biomarker for the 26S proteasome is the protein Trastuzumab (TIM-3), which is aG protein-coupled receptor (GPCR) that is involved in the regulation of cell growth and survival.TIM-3 has been shown to be involved in the regulation of the 26S proteasome and has been suggested as a potential drug target for the 26S proteasome.

Targeting the 26S proteasome using small molecules or antibodies that specifically target CAK or SIRT6 may be a promising strategy for

Protein Name: Proteasome 26S

The "Proteasome 26S Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about Proteasome 26S comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets